FR0012432516 - Common Stock
POXEL SA
EPA:POXEL (9/6/2024, 7:00:00 PM)
0.56
-0.01 (-1.06%)
Poxel SA operates as a clinical-stage biopharmaceutical company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2015-02-06. The firm develops drugs with a focus on Type 2 diabetes. The firm aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The firm cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
POXEL SA
Imm Le Sunway, 259/261 Avenue Jean Jaures
Lyon AUVERGNE-RHONE-ALPES
P: 33437372010
Employees: 30
Website: https://www.poxelpharma.com/
Find more stocks on Euronext Paris - Matif
Find more stocks on the EuroNext
Find more stocks on the European
Find competitors from the same sector on the EuroNext
Find competitors from the same industry on the EuroNext
Find stocks with similar TA and Setup ratings on the EuroNext
Find stocks with similar Fundamental rating on the EuroNext
Find the competitors with the best technical ratings on the EuroNext
Find the competitors with the best technical and setup ratings on the EuroNext
Find the competitors with the best fundamentals on the EuroNext
Find the competitors with the best valuation on the EuroNext
Find the competitors with the best dividend on the EuroNext
Find the competitors with the best analyst ratings on the EuroNext